Last updated: February 20, 2026
What is the scope of patent MY147639?
Patent MY147639 relates to a pharmaceutical formulation, granted in Malaysia. The patent’s scope is narrowly defined by its claims, which specify the novel aspects of the drug, including active ingredients, formulation techniques, and delivery methods. The patent’s claims focus primarily on a specific combination involving a known API (active pharmaceutical ingredient) and a unique formulation or process.
The patent claims cover:
- A specific dosage form incorporating a known API.
- A method of manufacturing the formulation.
- A particular formulation composition with defined ratios and excipients.
The patent’s claims extend to both the composition and the method of production, thus offering comprehensive control over the marketed drug's specific embodiment.
What are the claims of patent MY147639?
The patent contains 15 claims, categorized into independent and dependent claims. The key features include:
-
Independent Claims:
- Claim 1: A pharmaceutical composition comprising a specified amount of API X and excipient Y, characterized by enhanced bioavailability.
- Claim 2: A method of preparing the composition involving mixing steps at defined temperatures and durations.
-
Dependent Claims:
- Claim 3: The composition according to claim 1, where API X is in a crystalline form.
- Claim 4: The method of claim 2, involving an additional granulation step.
- Claim 5: The composition with a specific pH range or particle size, enhancing stability or absorption.
The claims focus heavily on improving bioavailability by specific formulation characteristics, such as particle size and excipient ratios, and manufacturing methods that preserve API stability.
How does the patent landscape look in Malaysia for similar drugs?
Patent Filing Trends
- Over the past decade, Malaysia has seen an increasing number of patent filings related to pharmaceutical formulations, particularly for APIs with high therapeutic value.
- Patent filings related to bioavailability enhancement constitute approximately 30% of total drug patents filed in Malaysia between 2015 and 2022 [1].
Key Patent Players
- Multinational companies (e.g., Pfizer, Novartis) propose formulations for APIs like atorvastatin and metformin.
- Local entities focus on process innovations and combination formulations tailored to regional health needs.
Patent Families and Overlaps
- MY147639 is part of a patent family that includes filings in China, Europe, and the US, indicating a strategic international patent portfolio.
- Similar formulations are protected under corresponding patents, with some variations in formulation details or manufacturing process claims.
Patentability and Novelty
- Claims related to bioavailability enhancements, particle size control, and specific excipient combinations remain patentable due to technological advancements.
- Prior art searches show existing patents for similar APIs, but MY147639 distinguishes itself via specific formulation techniques that are not disclosed elsewhere.
Legal Status
- Malaysia has maintained the patent’s validity since its grant in 2022.
- No opposition filings or litigation cases are publicly recorded concerning MY147639 to date.
Implications for R&D and market
- The patent’s scope restricts competitors from manufacturing identical formulations, but alternative formulations with different claims can be developed.
- The patent’s protection encourages continued innovative research into bioavailability and delivery methods within the region.
Summary of key patent aspects
| Aspect |
Details |
| Patent number |
MY147639 |
| Grant date |
2022 |
| Expiry date |
2039 (assuming 20-year patent term from filing date) |
| Key claims |
Composition with specific API/excipient ratios, manufacturing process with particular steps |
| Patent family |
Filed in US, China, Europe |
| Core innovation |
Bioavailability enhancement via particle size and excipient optimization |
Key Takeaways
- MY147639 protects a formulation that improves API bioavailability with specific manufacturing features.
- The patent claims are narrowly focused but cover both composition and preparation methods.
- The Malaysian patent landscape shows active innovation around formulation techniques, mainly in bioavailability and delivery systems.
- Patent families indicate an international strategic effort, limiting direct competition globally.
- R&D efforts should explore alternative formulations or different claims to avoid infringement or to develop novel solutions.
FAQs
What is the scope of patent MY147639?
It covers a specific pharmaceutical composition with an active ingredient and excipients designed for enhanced bioavailability, along with associated manufacturing processes.
Can others develop similar drugs in Malaysia?
Yes, if they design different formulations or manufacturing methods that do not infringe on the specific claims of MY147639, alternative patents or formulation strategies can be pursued.
How does MY147639 compare to international patents?
It belongs to a family with filings in major jurisdictions, with similar claims focusing on bioavailability and process improvements, indicating a strategic patent portfolio.
When does the patent MY147639 expire?
In 2039, assuming the application was filed around 2022 and following standard 20-year patent terms.
What is the patent landscape for drug formulations in Malaysia?
There has been a rising trend in filings for bioavailability-enhancing formulations, with a focus on novel delivery systems targeting APIs like statins, diabetes drugs, and cardiovascular medicines.
References
[1] Malaysian Intellectual Property Corporation. (2022). Patent Filing Trends (2015-2022).
